We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+9.7%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$300M
Cap. Flow
+$374M
Cap. Flow %
23.51%
Top 10 Hldgs %
49.78%
Holding
111
New
24
Increased
22
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$67.1M
2
NVCR icon
NovoCure
NVCR
+$58M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.1M
4
AZN icon
AstraZeneca
AZN
+$28.6M
5
IART icon
Integra LifeSciences
IART
+$27.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$35.3M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$33.2M
3
RVMD icon
Revolution Medicines
RVMD
+$25.4M
4
TXG icon
10x Genomics
TXG
+$21.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 83.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PODD icon
101
Insulet
PODD
$9.65B
– –
-16,750
Closed -$3.9M
RLAY icon
102
Relay Therapeutics
RLAY
$4.3B
– –
-910,000
Closed -$6.44M
SLN
103
Silence Therapeutics
SLN
$554M
– –
-260,000
Closed -$4.73M
SMMT icon
104
Summit Therapeutics
SMMT
$10.8B
– –
-285,000
Closed -$6.24M
SNY icon
105
Sanofi
SNY
$104B
– –
-612,000
Closed -$35.3M
TMCI icon
106
Treace Medical Concepts
TMCI
$284M
– –
-887,941
Closed -$5.15M
TNGX icon
107
Tango Therapeutics
TNGX
$4.72B
– –
-343,152
Closed -$2.64M
TXG icon
108
10x Genomics
TXG
$5.79B
– –
-951,000
Closed -$21.5M
VCYT icon
109
Veracyte
VCYT
$3.71B
– –
-54,303
Closed -$1.85M
NARI
110
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-93,878
Closed -$3.87M
LBPH
111
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-318,269
Closed -$10.6M
1 2 3 4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Soleus Capital Management held 111 positions worth $1.59B, up 23% from $1.29B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management deployed $374M of net new capital in Q4 2024, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $25.4M trimmed.

  • Soleus Capital Management's largest Q4 2024 buy was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.
  • Soleus Capital Management added most to Krystal Biotech in Q4 2024, an estimated $25.1M increase.
  • Soleus Capital Management's biggest Q4 2024 reduction was Revolution Medicines, cutting an estimated $25.4M.
  • Soleus Capital Management fully exited Sanofi in Q4 2024, selling an estimated $35.3M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $1.59B portfolio in Q4 2024.
  • Soleus Capital Management opened 24 new positions and closed 30 in Q4 2024.
  • Soleus Capital Management's portfolio value rose 23% quarter-over-quarter to $1.59B.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.